NCT06624644 - A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Biotech Hunter

Enrollment

135

Participants

Timeline

Start Date

August 6, 2025

Primary Completion Date

February 28, 2029

Study Completion Date

February 28, 2031

Conditions

Melanoma (Skin Cancer)Melanoma Stage IIIB-IVCutaneous MelanomaUnresectable Melanoma

Interventions

BIOLOGICAL

LNS8801

G protein-coupled estrogen receptor (GPER) agonist

BIOLOGICAL

Pembrolizumab

Recombinant monoclonal antibody (anti-PD1)

DRUG

Chemotherapy (dacarbazine or temozolomide)

chemotherapy (dacarbazine, temozolomide)

BIOLOGICAL

Immunotherapy (Pembrolizumab)

pembrolizumab

BIOLOGICAL

Immunotherapy (nivolumab and relatlimab)

nivolumab and relatlimab

BIOLOGICAL

Immunotherapy (ipilimumab and nivolumab)

ipilimumab and nivolumab

Trial Locations (7)

19107

RECRUITING

UPenn, Philadelphia

80045

RECRUITING

University of Colorado Anschutz, Aurora

87106

RECRUITING

University of New Mexico, Albuquerque

92663

RECRUITING

USC Newport Beach, Newport Beach

94143

RECRUITING

UCSF, San Francisco

94305

RECRUITING

Stanford, Stanford

02215

RECRUITING

Dana Farber, Boston